Stock Track | CARSGEN-B Soars 10.92% Intraday as CAR-T Therapy Research Published in The Lancet

Stock Track04-20

CARSGEN-B's stock price surged 10.92% during intraday trading on Monday. The significant upward movement reflects a sharp increase in investor confidence following a major scientific development for the company.

The catalyst for the rally was the official publication of research results for the company's independently developed Zevorcabtagene Autoleucel injection in The Lancet, one of the world's most prestigious medical journals. This publication marks a notable breakthrough in the challenging field of solid tumor CAR-T cell therapy, an area considered a critical unmet medical need.

Market participants interpreted the recognition from such an authoritative journal as a strong validation of the company's scientific progress and competitive positioning within the global cell therapy landscape. Consequently, expectations for the future commercialization prospects of this core pipeline asset were substantially elevated, driving the positive re-rating of the stock.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1102592704?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-20 09:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1102592704","market":"nz","top_or_hot":-1,"title":"Stock Track | CARSGEN-B Soars 10.92% Intraday as CAR-T Therapy Research Published in The Lancet","media":"Stock Track","content":"<p>CARSGEN-B's stock price surged 10.92% during intraday trading on Monday. The significant upward movement reflects a sharp increase in investor confidence following a major scientific development for the company.</p><p>The catalyst for the rally was the official publication of research results for the company's independently developed Zevorcabtagene Autoleucel injection in The Lancet, one of the world's most prestigious medical journals. This publication marks a notable breakthrough in the challenging field of solid tumor CAR-T cell therapy, an area considered a critical unmet medical need.</p><p>Market participants interpreted the recognition from such an authoritative journal as a strong validation of the company's scientific progress and competitive positioning within the global cell therapy landscape. Consequently, expectations for the future commercialization prospects of this core pipeline asset were substantially elevated, driving the positive re-rating of the stock.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | CARSGEN-B Soars 10.92% Intraday as CAR-T Therapy Research Published in The Lancet</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | CARSGEN-B Soars 10.92% Intraday as CAR-T Therapy Research Published in The Lancet\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-20 09:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CARSGEN-B's stock price surged 10.92% during intraday trading on Monday. The significant upward movement reflects a sharp increase in investor confidence following a major scientific development for the company.</p><p>The catalyst for the rally was the official publication of research results for the company's independently developed Zevorcabtagene Autoleucel injection in The Lancet, one of the world's most prestigious medical journals. This publication marks a notable breakthrough in the challenging field of solid tumor CAR-T cell therapy, an area considered a critical unmet medical need.</p><p>Market participants interpreted the recognition from such an authoritative journal as a strong validation of the company's scientific progress and competitive positioning within the global cell therapy landscape. Consequently, expectations for the future commercialization prospects of this core pipeline asset were substantially elevated, driving the positive re-rating of the stock.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02171","symbol_name":"科济药业-B","start_time":0,"source_url":"","article_id":"1102592704","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1102592704","pubTimestamp":1776649210,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"CARSGEN-B's stock price surged 10.92% during intraday trading on Monday. The significant upward movement reflects a sharp increase in investor confidence following a major scientific development for...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02171":"科济药业-B"},"translate_title":"个股追踪|CAR-T疗法研究发表在《柳叶刀》上科济安-B盘中大涨10.92%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02171":1},"content_text":"CARSGEN-B's stock price surged 10.92% during intraday trading on Monday. The significant upward movement reflects a sharp increase in investor confidence following a major scientific development for the company.The catalyst for the rally was the official publication of research results for the company's independently developed Zevorcabtagene Autoleucel injection in The Lancet, one of the world's most prestigious medical journals. This publication marks a notable breakthrough in the challenging field of solid tumor CAR-T cell therapy, an area considered a critical unmet medical need.Market participants interpreted the recognition from such an authoritative journal as a strong validation of the company's scientific progress and competitive positioning within the global cell therapy landscape. Consequently, expectations for the future commercialization prospects of this core pipeline asset were substantially elevated, driving the positive re-rating of the stock.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1102592704","isCrawlerRequest":true}